The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019
Open accessAbstract
Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. One trial was trending positive while the other showed no benefits from aducanumab. Post hoc analyses led the sponsor to assert that there was a sufficient efficacy signal to justify a new drug application as a treatment for Alzheimer's disease. The sponsor claimed that subsets of participants receiving sufficiently high doses of aducanumab demonstrated benefits in both trials. In contrast, we identified alternative accounts for the apparent drug benefits in post hoc subgroups that are unrelated to dose effects. Biomarker data were consistent with target engagement, but no evidence was presented to correlate biomarker changes to cognitive benefits. Our analysis supports the conduct of a third, phase III trial with high‐dose aducanumab. Aducanumab's efficacy as a treatment for the cognitive dysfunction in Alzheimer's disease cannot be proven by clinical trials with divergent outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies such as those by Salloway et al. and Biogen’s EMERGE and ENGAGE trials found that treating the plaques alone did not rescue cognitive defects (Knopman et al., 2021; Salloway et al., 2014).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Knopman et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“however, thus far, treatments to decrease formation of plaques have shown only minimal or no improvement in disease progression or outcomes (Knopman et al., 2021; Selkoe, 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Knopman et al., 2021
In the citing paper
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [7]
In the citing paper
“In spite of this, the FDA granted expedited approval on the grounds of the EMERGE trial’s documented decrease in amyloid levels [132,185,186,187].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [185]
In the citing paper
“Aducanumab demonstrated inconsistent outcomes in its two main clinical trials, the Phase III EMERGE and ENGAGE research investigations.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [185]
In the citing paper
“In the EMERGE experiment, when participants with AD were at risk for cognitive deterioration, there was a decrease in the amount of amyloid-beta plaques.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [185]
In the citing paper
“However, it is considered controversial due to the lack of sufficient evidence to support its efficacy.348,349”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [348]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A. R., Kamath, T. V., De Los Santos, M. B., Klickstein, N., Corjuc, D. L., Corjuc, B. T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0938-9 · Cited by 438
Sutphen, C. L., McCue, L., Herries, E. M., Xiong, C., Ladenson, J. H., Holtzman, D. M., Fagan, A. M., & On behalf of, A. D. N. I. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.012 · Cited by 162
Salloway, S., Honigberg, L. A., Cho, W., Ward, M. E., Friesenhahn, M. J., Brunstein, F., Quartino, A. L., Clayton, D., Mortensen, D. L., Bittner, T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0424-5 · Cited by 156
Cited by
Sorted by citations
Items 401–500 of 536
Vamanu, A., Maștaleru, A., Schreiner, T. G., Popescu, G., Roceanu, A. M., Cucu, A. I., Patrascu, A., Vulpoi, G.-A., Bilcu, R.-V., Cozma, S. R., et al. (2026) · Medical Sciences · doi:10.3390/medsci14030337 · Cited by 1
Bhati, S. S., & Tanwar, S. S. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00295-0 · Cited by 1
“However, conflicting results in the EMERGE and ENGAGE trials led to debates about aducanumab’s efficacy, with some researchers suggesting alternative explanations for apparent benefits in post hoc subgroups [50].”
Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025
Li, C., Fu, M., Berg, K., Wallach, J. D., Ling, K., Wei, R., Shi, L., Ross, J. S., & Guan, X. (2026) · Neurology · doi:10.1212/wnl.0000000000218373 · Cited by 1
Xue, W.-Y., Li, X., Li, W., Qin, B.-Z., Wang, C.-Z., Liu, T., & Wang, M. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261473013 · Cited by 2
“20 These challenges make post-marketing pharma-covigilance particularly important for anti-A β therapies.”
Godinho, W. D. N., Filho, F. S. L. V., Amaral, C. M. L., Guedes, M. I. F., de Serpa, G. L., Loureiro, A. C. C., Ceccatto, V. M., & Soares, P. M. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07397-5 · Cited by 1
ELEMENTARY PATHOPHYSIOLOGY, TREATMENT, RISK FACTOR OF ALZHEIMER’S DISEASE
(2022) · International Research Journal of Modernization in Engineering Technology and Science · doi:10.56726/irjmets30873 · Cited by 2
Sasaki, R., Suico, M. A., Chosa, K., Teranishi, Y., Sato, T., Kagami, A., Kotani, S., Kato, H., Hitora, Y., Tsukamoto, S., et al. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.11.004 · Cited by 1
Brain entrainment by audio-visual gamma frequency stimulations
Yi, Z., & Wang, W. (2022) · International Conference on Bioinformatics and Biomedical Science (ICBBS) · doi:10.1145/3571532.3571551 · Cited by 1
Neurodegenerative Erkrankungen
Seifert, R., & Petri, S. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_28 · Cited by 1
Zhang, J. (2023) · Inflammation Research · doi:10.1007/s00011-023-01788-y · Cited by 1
Royall, D. R., & Palmer, R. F. (2023) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2023.100184 · Cited by 1
Baksh, R. A., Strydom, A., Carter, B., Carrière, I., & Ritchie, K. A. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12563
How Attribution Theory Helps to Explain Psychiatric Nosology
Garrett, M. D. (2024) · American Journal of Health Research · doi:10.11648/j.ajhr.20241204.13 · Cited by 1
Phytocannabinoids: a new frontier in Alzheimer’s disease management
Rao, J. S. (2024) · Academia Biology · doi:10.20935/acadbiol7344 · Cited by 1
Mundel, K. K., & Cooper, C. R. (2024) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.686
Yu, Y., Deng, J., Yang, X., Wu, J., Yu, R., & Guo, C. (2025) · Brain and Behavior · doi:10.1002/brb3.70352 · Cited by 1
“…to be a key mechanism for developing AD, and specific drugs targeting this mechanism have been developed, such as lecanemab and aducanumab, these therapies have shown limitedclinicalefficacyinhaltingorreversingdiseaseprogression (Weller and Budson 2018; van Dyck et al. 2023; Knopman et al. 2021).”
Chettupalli, A. K., Gupta, N., Bukke, S. P. N., Singh, M. P., & Mandal, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118803 · Cited by 1
In situ neuroregeneration: frontiers and therapeutic prospects
Wang, Q., Li, W., Lei, W., Chen, W., Zheng, J., Xiang, Z., MinHui, L. I. U., He, Q., Xu, L., Li, Z., et al. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0024 · Cited by 1
Chen‐Plotkin, A. S. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.031 · Cited by 1
Erstes kausal wirkendes Medikament gegen Alzheimer?
Häger, K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01182-1 · Cited by 1
Massetti, N., Granzotto, A., Bomba, M., Pizzi, S. D., Mosca, A., Scherer, R., ONOFRJ, M. C., Sensi, S. L., & (ADNI), F. T. A. D. N. I. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.119015 · Cited by 1
New Perspectives for Treatment in Alzheimer’s Disease
Loureiro, J. C., Silva, L. F. D. A. L. E., Pais, M. V., & Forlenza, O. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_10 · Cited by 1
Gomaa, A. A., Farghaly, H. S. M., Makboul, R. M., Hussien, A. M., & Nicola, M. A. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03765-0 · Cited by 1
“It is the first new drug approved for the treatment of AD since 2003 [1].”
BackgroundRetractedMedicinal Cannabis for Alzheimer's Disease
Steiner, G. Z., Coles, M., Jaye, K. M., Metri, N., Butt, A. S., Christofides, K., McPartland, J., Al-Modhefer, Z., Karamacoska, D., Russo, E. B., et al. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5652-1.ch001 · Cited by 1
Lushington, G. H. (2021) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620732501210915141707 · Cited by 1
Predicting Abnormal Amyloid Burden
Eshaghi, A., & Buckley, R. F. (2022) · Neurology · doi:10.1212/wnl.0000000000200721 · Cited by 1
Paez, J. A., González-Naranjo, P., Pérez, C., González‐Sánchez, M., Gironda-Martínez, A., Ulzurrun, E., Bartolomé, F. B., Rubio‐Fernández, M., Martı́n, M. I., & Campillo, N. E. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4052313 · Cited by 1
Bernardo, A. M., Marcotte, M. D., Wong, K. D., Sharmin, D., Pandey, K. P., Cook, J. M., Sibille, E. L., & Prévot, T. D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.30.510361 · Cited by 1
Prediction of misfolded proteins spreading in Alzheimer’s disease using machine learningPreprint
Gherardini, L., Pestka, A., Pini, L., & Crimi, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.04.510701 · Cited by 1
Nemergut, M., Marques, S. M., Uhrík, L., Váňová, T., Nezvedová, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.09.511473 · Cited by 1
Litke, R. R., Vicari, J. M., Huang, B. T., Shapiro, L. R., Roh, K.-H., Silver, A. E., Talreja, P., Palacios, N., Yoon, Y., Kellner, C. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.12.544352 · Cited by 1
A SCOPING REVIEW OF ALZHEIMER’S DISEASE HYPOTHESES: THE CASE FOR A MULTI-FACTORIAL THEORYPreprint
Duchesne, S., Rousseau, L., Belzile, F., Welsh, L.-A., Cournoyer, B., Arseneau, M., Lapierre, V., Poulin, S., Potvin, O., & Hudon, C. (2023) · medRxiv · doi:10.1101/2023.07.26.23293030 · Cited by 1
“to reach meaningful clinical changes (9), even when compared to those few that succeeded with modest (but, to be fair, statistically significant) success (10).”
Industry Update Covering November 2020
SIMPSON, I. A. (2021) · Therapeutic Delivery · doi:10.4155/tde-2021-0002
The Longevity Industry Dilution Conundrum
Björk, V. (2021) · Rejuvenation Research · doi:10.1089/rej.2021.0038
caso de aducanumab ¿Más esperanza que ciencia?
Sánchez-Montoya, E., Andresen, M., Corrales, R., Gallardo, J., Noriega, V., & Oppenheimer, C. W. (2021) · ARS MEDICA Revista de Ciencias Médicas · doi:10.11565/arsmed.v46i3.1826 · Cited by 1
Restoration of Calmodulin-Like Skin Protein as Treatment for Alzheimer's Disease
Matsuoka, M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.771856
Aducanumab: falta de consistencia entre la evidencia preclínica y clínica
Ardiles, Á. O., Marcelo Arancibia, M., Lutz, M., Riquelme, J., Gigoux, J. P., & Muñoz, P. (2021) · Revista médica de Chile · doi:10.4067/s0034-98872021000600950
Aducanumab na Doença de Alzheimer: Percurso e Perspetiva
Rema, J., & do Couto, F. S. (2022) · Revista Portuguesa de Psiquiatria e Saúde Mental · doi:10.51338/rppsm.308
(2021) · Alzheimer s & Dementia · doi:10.1002/alz.12354
Novel perspectives from existing data on early Alzheimer’s disease pathology and dementia care use
Janssen, O. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220617oj
Wu, K., Xu, C., Tian, X., Qiu, G., Liu, W., Guo, Q., Chen, C., Liu, J., Guo, Z., Chen, H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4125474
Effects of Aducanumab on treating Alzheimer’s disease: targets and clinical trials
Huang, B. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v6i.973
“Heterogeneity existed among AD of different patients in the different quantity of plaque and the causative agent of the disease: whether it is p-Tau and t-Tau pathways [19].”
BackgroundAducanumab for Alzheimer’s disease: Observations and opportunities
Pridmore, W. (2022) · Australasian Psychiatry · doi:10.1177/10398562221121215
Ballesteros‐Álvarez, J., Nguyen, W., Sivapatham, R., Rane, A., & Andersen, J. K. (2022) · Research Square · doi:10.21203/rs.3.rs-2046848/v2
Age-specific activation of microglial genes in a mouse model of ADPreprint
Zhou, H., & Yu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.28.514172
Ending Clinical Trials Prematurely
Streiner, D. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-99680-2_26
Harrison, C. H., Sakai, K., Johnston, D. A., Holmes, C., Boche, D., & Nicoll, J. A. R. (2022) · medRxiv · doi:10.1101/2022.12.08.22283144
Treatment concept successfully translated into human patients
Hermann, D. M. (2023) · Exploration of neuroscience · doi:10.37349/en.2023.00011
IMPACTS OF HYPERTENSION AND THROMBOSIS IN A RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY (rTg-DI)
Stanisavljevic, A. (2022) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-stanisavljevic-aleksandra-2022
The potential of extracellular vesicle lipid profiling in Alzheimer's disease.Preprint
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · doi:10.22541/au.168388562.25020996/v1
The Mechanism of Retinal Laser and Its End Result: Neuroprotecion
Luttrull, J. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-25779-7_14
Cuní‐López, C., Stewart, R., Okano, S., Redlich, G. L., Appleby, M. W., White, A. R., & Quek, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.17.552618
A Novel Pathogenic Tau Conformer Playing Part in Tau Pathology in Human Neurons Upon Aging StressPreprint
Tofigh, N., Agahi, S., Riazi, G. H., Pakdaman, H., Moazzam, M. G., & Shahpasand, K. (2023) · Research Square · doi:10.21203/rs.3.rs-3355775/v1
Anti-amyloid Monoclonal Antibodies in Alzheimer’s Disease: A New Hope
Nasibova, A. N., Khalilov, R. I., & Eftekhari, A. (2023) · International Journal of Aging · doi:10.34172/ija.2023.e21 · Cited by 1
“13,43 Fortunately, several follow-up studies involving the Emerge and Engage groups revealed that aducanumab-treated individuals in the Engage group have a modest drop in the CDR-SB parallel to the Emerge group alterations (Table 1).”
BackgroundBayesian hierarchical modeling in interim futility analysis for two parallel clinical trials
Li, H., Roy, D., & Deng, Q. (2023) · Statistics in Medicine · doi:10.1002/sim.9971
“8,6 One fundamental assumption that needs to hold in order to gain from such combined interim analyses is that the studies with similar designs would lead to similar study results.”
ResultGoo, C., Morden, F. T. C., Wong, K., Aquino, S., Kawamura, J., Rubel, V., Masca, S., Gorenflo, R., Carrazana, E. J., & Liow, K. K. (2023) · Cureus · doi:10.7759/cureus.50001
“Results showed a dose-and-time-dependent reduction in beta-amyloid pathology with aducanumab in phase 3 studies of EMERGE but not ENGAGE [2].”
BackgroundThe Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
Gibbs, D. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009430067.028
Popp, J. H., Jutkowitz, E., & Trikalinos, T. A. (2024) · medRxiv · doi:10.1101/2024.02.13.24302771
Petri, S., & Seifert, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_28
Human Stem Cells and Their Future Application in Neurodegenerative Diseases
Barthels, D., Prateeksha, P., & Das, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00073-1
Beta amyloid PET scans for dementia diagnoses: Practice and research implications from CARE‐IDEAS
Wetle, T. T., Houtven, C. H. V., Shepherd‐Banigan, M. E., Bélanger, E., Couch, E., Sorenson, C., Gadbois, E. A., Burke, J. R., Jutkowitz, E., O'Brien, E. C., et al. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19008
“5,6 9 Although these and other treatments to improve or slow progression of symptoms of AD have yet to be proven substantially effective, 10,11 several potential interventions are under study and the hope for a treatment that could delay symptoms at early stages makes access to an early and…”
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsPreprint
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., & Initiative, A. D. N. (2024) · medRxiv · doi:10.1101/2024.09.03.24312481
3T sodium-MRI as predictor of neurocognition in nondemented older adults: a cross sectional study
LUI, E. H., Venkatraman, V. K., Finch, S. J., Chua, M., Li, T., Sutton, B. P., Steward, C. E., Moffat, B. A., Cyarto, E., Ellis, K. A., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae307
“However, more data on clinical efficacy through a demonstratable slowing of cognitive decline (beyond surrogate neuropathologic endpoints such as amyloid clearance) is needed to non-controversially justify the widespread use of these DMT. 3,4 MRI is used to monitor side effects in DMT clinical trials, such as amyloid-…”
BackgroundKollarik, S., Bimbiryte, D., Sethi, A., Dias, I., Moreira, C. G., & Noaín, D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.02.616223
“Moreover, the unsuccessful clinical translation of positive results obtained from targeting the late phases of AD in animal models (Knopman, Jones, & Greicius, 2021; Tampi, Forester, & Agronin, 2021) calls for novel therapeutic strategies focusing on prevention and/or delaying the onset of AD…”
BackgroundWang, R., Jian, Z., Yu, L., & Wang, C. (2024) · Scientia Sinica Chimica · doi:10.1360/ssc-2024-0194
New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
Joodaki, M., Shirazi, M. M., & Hosseini, N. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.3.219
张, 苹. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123241
Petri, S., & Seifert, R. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_28
Catto, F., Dadgar‐Kiani, E., Kirschenbaum, D., Economides, A. E., Reuss, A. M., Trevisan, C., Caredio, D., Delic, M., Frick, L. D., Weber‐Stadlbauer, U., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0309489
Kong, F., Zhang, W., Wu, T., Jingyi, D. A. I., Xu, Y. C., & Sun, T. (2025) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2025.100560
Biomarkers as Outcome Measures in Clinical Trials of Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_15
Progress in the Study of the Pathogenesis of AD and Its Treatment Based on Lecanemab
He, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au25014
Why don’t we have a cure for Alzheimer’s disease?
Weaver, D. F. (2021) · doi:10.64628/aam.5xk75evke
The Evolving Landscape of Amyloid Research
Bonilauri, B. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70048
“Possible factors include the COVID-19 pandemic [47], setbacks in drug development [48–50], and controversies in Alzheimer's and Parkinson's research [51, 52].”
Understanding the Silent Threat: A Review to Neurodegenerative Disorders
Kajrolkar, A. (2025) · Premier Journal of Neuroscience · doi:10.70389/pjn.100012 · Cited by 1
Potential anti-amyloid beta oligomerization effects of PD166793 in Alzheimer's disease
Kim, D., Shim, K., Kim, J., Ko, G., Tan, M. A., Chang, K.-A., & An, S. S. A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115504
Cuní‐López, C., Stewart, R., Oikari, L. E., Nguyen, T. H., Roberts, T. L., Sun, Y., Guo, C. C., Lupton, M. K., White, A. R., & Quek, H. (2024) · Figshare · doi:10.6084/m9.figshare.25237419
Nemergut, M., Marques, S. M., Uhrík, L., Váňová, T., Nezvedová, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304976
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618647
Nemergut, M., Marques, S. M., Uhrík, L., Váňová, T., Nezvedová, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304964
Young, J. J., Park, H.-J., Kim, M., Par‐Young, J., Bartlett, H. H., Kim, H. S., Ünlü, S., Osmani, L., Shin, M. S., Bucala, R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24716931
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618659
Cuní‐López, C., Stewart, R., Oikari, L. E., Nguyen, T. H., Roberts, T. L., Sun, Y., Guo, C. C., Lupton, M. K., White, A. R., & Quek, H. (2024) · Figshare · doi:10.6084/m9.figshare.26681788
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618662
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618650
Cuní‐López, C., Stewart, R., Oikari, L. E., Nguyen, T. H., Roberts, T. L., Sun, Y., Guo, C. C., Lupton, M. K., White, A. R., & Quek, H. (2024) · Figshare · doi:10.6084/m9.figshare.25237386
Cuní‐López, C., Stewart, R., Oikari, L. E., Nguyen, T. H., Roberts, T. L., Sun, Y., Guo, C. C., Lupton, M. K., White, A. R., & Quek, H. (2024) · Figshare · doi:10.6084/m9.figshare.26681785
Young, J. J., Park, H.-J., Kim, M., Par‐Young, J., Bartlett, H. H., Kim, H. S., Ünlü, S., Osmani, L., Shin, M. S., Bucala, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24716955
Oliver, M. D., Morrison, C., Kamal, F., Graham, J., & Dadar, M. (2024) · Figshare · doi:10.6084/m9.figshare.26558042
Cuní‐López, C., Stewart, R., Oikari, L. E., Nguyen, T. H., Roberts, T. L., Sun, Y., Guo, C. C., Lupton, M. K., White, A. R., & Quek, H. (2024) · Figshare · doi:10.6084/m9.figshare.26681791
Pini, L., de Lange, S. C., Pizzini, F. B., Galazzo, I. B., Manenti, R., Cotelli, M., Galluzzi, S., Cotelli, M. S., Corbetta, M., van den Heuvel, M. P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608796
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618653
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618668
Dickson, S. P., Hennessey, S., Nicodemus‐Johnson, J., Knowlton, N., & Hendrix, S. B. (2023) · Figshare · doi:10.6084/m9.figshare.23167607
Wright, E. B., Larsen, E. G., Coloma-Roessle, C. M., Hart, H. R., & Bhattacharya, M. R. C. (2024) · Figshare · doi:10.6084/m9.figshare.26618656
Nemergut, M., Marques, S. M., Uhrík, L., Váňová, T., Nezvedová, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304970
Cuní‐López, C., Stewart, R., Oikari, L. E., Nguyen, T. H., Roberts, T. L., Sun, Y., Guo, C. C., Lupton, M. K., White, A. R., & Quek, H. (2024) · Figshare · doi:10.6084/m9.figshare.26681779
Metadata
- Authors
- Knopman, D. S., Jones, D. T., & Greicius, M. D.
- Affiliations
- Mayo Clinic (US)
- Stanford Medicine (US)
- Corresponding author
- Knopman, David S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2020-11
- Volume
- 17
- Issue
- 4
- Pages
- 696-701
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W3097527510
- Cited by
- 524
- References
- 13
- Citations by year
- 2026: 53 · 2025: 55 · 2024: 75 · 2023: 107 · 2022: 151 · 2021: 79 · 2020: 4
- FWCI
- 51.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- aducanumab, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Amyloid, Dose-Response Relationship, Drug, Humans, Biomarkers, Treatment Outcome, Treatment Failure, Clinical Trials, Phase III as Topic, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
